Sydnexis, Inc., a pre-commercial stage biopharmaceutical company focused on the treatment of pediatric myopia, has appointed Perry J. Sternberg as Chief Executive Officer and as a member of the Board of Directors. Sternberg is an accomplished pharma/biotech executive with more than 30 years in the industry and 15 years in eye care. Perry will provide leadership experience to help guide Sydnexis’ strategic direction and next phase of growth.   Perry brings commercial leadership including ...